These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

64 related items for PubMed ID: 1953171

  • 21. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
    Chahine EB, Sourial M, Ortiz R.
    Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 25. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria.
    Chin NX, Neu HC.
    Am J Med; 1987 Apr 27; 82(4A):58-62. PubMed ID: 3578330
    [Abstract] [Full Text] [Related]

  • 26. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C, Sirham M, Labarca J, Grebe G, Lira P, Oliva J, Duhalde M, Ocqueteau M, Acuña G.
    Rev Med Chil; 1995 Mar 27; 123(3):312-20. PubMed ID: 8525170
    [Abstract] [Full Text] [Related]

  • 27. Bacterial pathogens (non-Mycobacterium) from sputum culture and antimicrobial susceptibility.
    Srifuengfung S, Sangsawang M, Komolpis P, Dhiraputra C, Chompanee B.
    Southeast Asian J Trop Med Public Health; 1998 Mar 27; 29(1):96-9. PubMed ID: 9740278
    [Abstract] [Full Text] [Related]

  • 28. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
    Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS.
    Clin Infect Dis; 2008 Mar 01; 46(5):647-55. PubMed ID: 18225981
    [Abstract] [Full Text] [Related]

  • 29. [In vitro activity of norfloxacin against gram-positive and gram-negative organisms from recent clinical isolates].
    Mancini C, Brenciaglia MI, Ghezzi MC, Giordano A, Nazzari C, Cipriani P.
    Boll Ist Sieroter Milan; 1985 Mar 01; 64(4):289-93. PubMed ID: 3935135
    [Abstract] [Full Text] [Related]

  • 30. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
    Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2010 Apr 01; 66(4):393-401. PubMed ID: 20022192
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Activity of cefoperazone and cefoperazone-sulbactam against gram-positive and gram-negative bacteria].
    Baykal M, Hasçelik G.
    Mikrobiyol Bul; 1990 Oct 01; 24(4):383-5. PubMed ID: 2287298
    [Abstract] [Full Text] [Related]

  • 33. Impact of an antibiotic restriction policy on the antibiotic resistance patterns of Gram-negative microorganisms in an Intensive Care Unit in Greece.
    Ntagiopoulos PG, Paramythiotou E, Antoniadou A, Giamarellou H, Karabinis A.
    Int J Antimicrob Agents; 2007 Oct 01; 30(4):360-5. PubMed ID: 17629680
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. In vitro antimicrobial activity of propolis and synergism between propolis and antimicrobial drugs.
    Stepanović S, Antić N, Dakić I, Svabić-Vlahović M.
    Microbiol Res; 2003 Oct 01; 158(4):353-7. PubMed ID: 14717457
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime.
    Pal RB, Pal P, Venkatesh V, Kulkarni KP.
    J Indian Med Assoc; 2008 Sep 01; 106(9):605-6, 611. PubMed ID: 19552092
    [Abstract] [Full Text] [Related]

  • 38. Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.
    Aronoff GR, Brier RA, Sloan RS, Brier ME.
    Antimicrob Agents Chemother; 1990 Jun 01; 34(6):1139-42. PubMed ID: 2203304
    [Abstract] [Full Text] [Related]

  • 39. Antimicrobial therapy in patients with impaired renal function.
    Aronoff GR.
    Am J Kidney Dis; 1983 Sep 01; 3(2):106-10. PubMed ID: 6613989
    [Abstract] [Full Text] [Related]

  • 40. Use of drugs in patients with renal insufficiency. Workshop report.
    Aronoff G, Brater DC, Schrier R, Bennett WM.
    Blood Purif; 1994 Sep 01; 12(1):14-9. PubMed ID: 7986472
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.